The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is currently approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) in combination with chemotherapy in first- and second-line and as monotherapy in chemorefractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Battaglin, Francesca, Puccini, Alberto, Ahcene Djaballah, Selma, Lenz, Heinz-Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607986/
https://www.ncbi.nlm.nih.gov/pubmed/31388315
http://dx.doi.org/10.2147/CMAR.S186042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607986/
https://www.ncbi.nlm.nih.gov/pubmed/31388315
http://dx.doi.org/10.2147/CMAR.S186042

Ejemplares similares